Physician profile
Benjamin E Levine
NPI 1871554329
$9,720.62
in general payments reported to CMS, 2019-2025
29 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,486 · 2020: $1,067 · 2021: $1,251 · 2022: $1,852 · 2023: $1,596 · 2024: $1,052 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,880 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,879.63 |
| Education | $184.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,539.77 | 2019-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $1,310.73 | 2019-2025 | |
| Amgen INC. | $1,284.53 | 2019-2025 | Krystexxa, Tavneos, Otezla |
| Glaxosmithkline, LLC. | $1,228.68 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals Lp | $513.60 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $493.25 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $278.74 | 2019-2023 | Rituxan, Actemra |
| Pfizer INC. | $268.15 | 2019-2025 | |
| Ucb, INC. | $227.94 | 2021-2023 | Cimzia |
| Bioventus LLC | $226.49 | 2019-2024 | Gelsyn-3 |
| Novartis Pharmaceuticals Corporation | $198.78 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $130.71 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $123.07 | 2022-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.67 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $102.40 | 2019-2025 | Orencia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $92.99 | 2020-2024 | |
| Mallinckrodt Enterprises LLC | $92.54 | 2019 | |
| Radius Health, INC. | $85.08 | 2019-2025 | Tymlos |
| Hikma Pharmaceuticals USA | $78.85 | 2019-2020 | |
| Medexus Pharma, INC. | $57.65 | 2019 | |
| Ani Pharmaceuticals, INC. | $53.72 | 2024-2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $53.52 | 2019-2020 | |
| Allergan, INC. | $44.74 | 2020 | |
| Organon LLC | $31.20 | 2023 | Renflexis, Hadlima |
| Orthofix Medical, INC. | $22.96 | 2020 | |
| Acell, INC. | $21.94 | 2019 | |
| Lilly USA, LLC | $18.19 | 2021 | |
| Gotham Surgical Solutions & Devices, INC. | $13.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.38 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.